57 related articles for article (PubMed ID: 18651120)
1. Epigenetics as a Key Factor in Prostate Cancer.
Enikeeva K; Rafikova G; Sharifyanova Y; Mulyukova D; Vanzin A; Pavlov V
Adv Biol (Weinh); 2024 May; 8(5):e2300520. PubMed ID: 38379272
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic alterations in human prostate cancers.
Nelson WG; De Marzo AM; Yegnasubramanian S
Endocrinology; 2009 Sep; 150(9):3991-4002. PubMed ID: 19520778
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma.
Wang Z; He W; Yang G; Wang J; Wang Z; Nesland JM; Holm R; Suo Z
BMC Cancer; 2010 Jul; 10():352. PubMed ID: 20602752
[TBL] [Abstract][Full Text] [Related]
4. [CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer].
Bastian PJ; Ellinger J; von Rücker A; Müller SC; Yegnasubramanian S; Nelson WG; Stief CG
Urologe A; 2008 Sep; 47(9):1205-7. PubMed ID: 18651120
[TBL] [Abstract][Full Text] [Related]
5. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
6. [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer].
Bastian PJ; Nakayama M; De Marzo AM; Nelson WG
Urologe A; 2004 May; 43(5):573-9. PubMed ID: 15029477
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
[TBL] [Abstract][Full Text] [Related]
8. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
[TBL] [Abstract][Full Text] [Related]
9. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
[TBL] [Abstract][Full Text] [Related]
10. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Rogers CG; Lin X; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
J Urol; 2008 Feb; 179(2):529-34; discussion 534-5. PubMed ID: 18076941
[TBL] [Abstract][Full Text] [Related]
11. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy.
Bastian PJ; Ellinger J; Heukamp LC; Kahl P; Müller SC; von Rücker A
Eur Urol; 2007 Mar; 51(3):665-74; discussion 674. PubMed ID: 16956712
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
